1. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Women's Health 2019:287-99. https://doi.org/10.2147%2FIJWH.S197604

2. Arora T, Mullangi S, Lekkala MR. Ovarian Cancer. StatPearls Publishing, Treasure Island (FL). 2021.

3. De Leo A, Santini D, Ceccarelli C, Santandrea G, Palicelli A, Acquaviva G, et al. What is new on ovarian carcinoma: integrated morphologic and molecular analysis following the new 2020 World Health Organization classification of female genital tumors? Diagnostics 2021;11(4):697. https://doi.org/10.3390/diagnostics11040697

4. Vang R, Gown AM, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, et al. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol 2006;19(11):1421-8. https://doi.org/10.1038/modpathol.3800698

5. Shin JH, Bae JH, Lee A, Jung C-K, Yim HW, Park J-S, et al. CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. Jpn J Clin Oncol 2010;40(3):208-13. https://doi.org/10.1093/jjco/hyp150

6. Wang Y, Liu L, Yu Y. Mucins and mucinous ovarian carcinoma: Development, differential diagnosis, and treatment. Heliyon 2023;9:e19221. https://doi.org/10.1016/j.heliyon.2023.e19221

7. Meagher NS, Wang L, Rambau PF, Intermaggio MP, Huntsman DG, Wilkens LR, et al. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Mod Pathol 2019;32(12):1834-46. https://doi.org/10.1038/s41379-019-0302-0

8. Dundr P, Singh N, Nožičková B, Němejcová K, Bártů M, Stružinská I. Primary mucinous ovarian tumors vs. ovarian metastases from gastrointestinal tract, pancreas and biliary tree: a review of current problematics. Diag Pathol 2021;16(1):1-17. https://doi.org/10.1186/s13000-021-01079-2

9. Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynecol Obstet 2021;155(1):61-85. https://doi.org/10.1002/ijgo.13878

10. Kubeček O, Laco J, Špaček J, Petera J, Kopecký J, Kubečková A, et al. The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review. Clin Exp Metast 2017;34(5):295-307. https://doi.org/10.1007/s10585-017-9856-8

11. Strickland S, Wasserman JK, Giassi A, Djordjevic B, Parra-Herran C. Immunohistochemistry in the diagnosis of mucinous neoplasms involving the ovary: the added value of SATB2 and biomarker discovery through protein expression database mining. Int J Gynecol Pathol 2016;35(3):191-208. https://doi.org/10.1097/PGP.0000000000000238

12. Mostafa NA, Fathi A. Validity of SATB2 in distinguishing metastatic mucinous carcinoma of colorectal origin from primary ovarian mucinous carcinoma. Egypt J Path 2020;18(1):4-9.

13. Montiel DP, Angulo KA, Cantú-de León D, Quevedo LB, Vilchis JC, Montalvo LH. The value of SATB2 in the differential diagnosis of intestinal-type mucinous tumors of the ovary: primary vs metastatic. Ann Diag Pathol 2015;19(4):249-52. https://doi.org/10.1016/j.anndiagpath.2015.05.004

14. Aldaoud N, Erashdi M, AlKhatib S, Abdo N, Al-Mohtaseb A, Graboski-Bauer A. The utility of PAX8 and SATB2 immunohistochemical stains in distinguishing ovarian mucinous neoplasms from colonic and appendiceal mucinous neoplasm. BMC Res Notes 2019;12(770):1-6. https://doi.org/10.1186%2Fs13104-019-4816-9

15. Li Z, Roth R, Rock JB, Lehman A, Marsh WL, Suarez A, et al. Dual immunostain with SATB2 and CK20 differentiates appendiceal mucinous neoplasms from ovarian mucinous neoplasms. Am J Clin Pathol 2017;147(5):484-91. https://doi.org/10.1093/ajcp/aqx023

16. Kurnit KC, Frumovitz M. Primary mucinous ovarian cancer: options for surgery and chemotherapy. Int J Gyne Can 2022;32(11). https://doi.org/10.1136/ijgc-2022-003806

17. Nasioudis D, Albright BB, Ko EM, Haggerty AF, Giuntoli RL, Burger RA, et al. Advanced stage primary mucinous ovarian carcinoma. Where do we stand? Arch Gynecol Obstet 2020;301:1047-54. https://doi.org/10.1007/s00404-020-05489-3